A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
This is a multi-center, multi-national, randomized, parallel-group, placebo-controlled,
double-blind study with a 17 week (maximum) treatment period consisting of an initial,
open-label dose titration (up to 2 weeks), followed by a washout period (up to 3 weeks),
followed by a 12 week treatment period on a stable dose.
Recruiting | Parkinson's Disease | Multisite
|
|